Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Abbott Reports Fourth-Quarter 2016 Results

- FOURTH-QUARTER GAAP EPS FROM CONTINUING OPERATIONS OF $0.51; ADJUSTED EPS FROM CONTINUING OPERATIONS OF $0.65

- ISSUES EPS OUTLOOK FOR 2017, REFLECTING DOUBLE-DIGIT GROWTH AT THE MID-POINT

- COMPLETED ACQUISITION OF ST. JUDE MEDICAL, CREATING A PREMIER MEDICAL DEVICE BUSINESS WITH LEADING POSITIONS IN SEVERAL LARGE AND HIGH-GROWTH AREAS


News provided by

Abbott

Jan 25, 2017, 06:45 ET

Share this article

Share toX

Share this article

Share toX

ABBOTT PARK, Ill., Jan. 25, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2016.

  • Reported diluted EPS from continuing operations under GAAP was $0.51 in the fourth quarter. Excluding specified items, adjusted diluted EPS from continuing operations was $0.65 in the fourth quarter, in-line with the previous guidance range.
  • Fourth-quarter worldwide sales of $5.3 billion increased 2.8 percent on a reported basis and 3.8 percent on an operational basis.
  • Full-year worldwide sales increased 2.2 percent on a reported basis and 4.8 percent on an operational basis.
  • Abbott issues full-year 2017 guidance range for diluted EPS from continuing operations under GAAP of $0.92 to $1.02, including intangible amortization and integration expenses related to the acquisition of St. Jude Medical. Excluding specified items, projected full-year 2017 adjusted diluted EPS from continuing operations is $2.40 to $2.50.   
  • In the fourth quarter, Abbott obtained CE Mark for four new major diagnostics systems, including "AlinityTM s" for blood and plasma screening, "Alinity i" for immunoassay diagnostics, "Alinity c" for clinical chemistry diagnostics and "i-STAT® Alinity" for point of care blood testing. Abbott's Alinity family of solutions are designed to be more efficient – running more tests in less space, generating test results faster and minimizing human errors – while continuing to provide quality results.
  • On Jan. 4, 2017, Abbott completed the acquisition of St. Jude Medical, establishing the company as a leader in the broad medical device arena and providing expanded opportunities for future growth. With the acquisition, Abbott now competes in nearly every area of the $30 billion cardiovascular device market and holds No. 1 or 2 positions across several large and high-growth cardiovascular device areas.

"2016 was a very important year for Abbott," said Miles D. White, chairman and chief executive officer, Abbott. "We achieved our financial commitments, advanced our internal pipeline, and took important strategic steps to shape the company for balance and growth."


FOURTH-QUARTER BUSINESS OVERVIEW

Following are sales by business segment and commentary for the fourth quarter and the full year:

Total Company
($ in millions)









% Change vs. 4Q15



Sales 4Q16




Int'l


Total



U.S.


Int'l


Total


U.S.


Reported


Operational


Reported


Operational

Total *


1,655


3,678


5,333


3.2


2.6


4.1


2.8


3.8

Nutrition


745


988


1,733


2.7


(8.1)


(6.3)


(3.7)


(2.6)

Diagnostics


375


881


1,256


2.0


3.3


4.8


2.9


3.9

Established Pharmaceuticals

--


979


979


 n/a 


10.6


12.6


10.6


12.6

Medical Devices


527


827


1,354


4.7


4.2


4.7


4.4


4.7


 * Total Abbott Sales from continuing operations include Other Sales of $11 million.











% Change vs. 12M15



Sales 12M16




Int'l


Total



U.S.


Int'l


Total


U.S.


Reported


Operational


Reported


Operational

Total *


6,486


14,367


20,853


3.4


1.6


5.4


2.2


4.8

Nutrition


2,969


3,930


6,899


3.5


(4.3)


(0.5)


(1.1)


1.2

Diagnostics


1,437


3,376


4,813


3.2


3.8


6.5


3.6


5.5

Established Pharmaceuticals

--


3,859


3,859


 n/a 


3.7


10.5


3.7


10.5

Medical Devices


2,047


3,186


5,233


3.2


4.1


5.4


3.8


4.5


* Total Abbott Sales from continuing operations include Other Sales of $49 million.

n/a = Not Applicable.

Note: Operational growth reflects percentage change over the prior year excluding the impact of exchange rates. In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

Fourth-quarter 2016 worldwide sales of $5.3 billion increased 2.8 percent on a reported basis, including an unfavorable 1.0 percent effect of foreign exchange, and increased 3.8 percent on an operational basis.

Full-year 2016 worldwide sales increased 2.2 percent on a reported basis and 4.8 percent on an operational basis.

Nutrition
($ in millions)        









% Change vs. 4Q15



Sales 4Q16




Int'l


Total



U.S.


Int'l


Total


U.S.


Reported


Operational


Reported


Operational

Total


745


988


1,733


2.7


(8.1)


(6.3)


(3.7)


(2.6)

Pediatric


435


542


977


6.2


(13.1)


(11.2)


(5.4)


(4.3)

Adult


310


446


756


(1.8)


(1.2)


0.6


(1.4)


(0.4)



























% Change vs. 12M15



Sales 12M16




Int'l


Total



U.S.


Int'l


Total


U.S.


Reported


Operational


Reported


Operational

Total


2,969


3,930


6,899


3.5


(4.3)


(0.5)


(1.1)


1.2

Pediatric


1,677


2,206


3,883


5.3


(7.2)


(3.5)


(2.2)


--

Adult


1,292


1,724


3,016


1.3


(0.4)


3.7


0.3


2.7

Worldwide Nutrition sales decreased 3.7 percent on a reported basis in the fourth quarter, including an unfavorable 1.1 percent effect of foreign exchange, and decreased 2.6 percent on an operational basis. 

Worldwide Pediatric Nutrition sales decreased 5.4 percent on a reported basis in the fourth quarter, including an unfavorable 1.1 percent effect of foreign exchange, and decreased 4.3 percent on an operational basis. In the U.S., above-market sales growth was led by Abbott's PediaSure® toddler brand as well as continued uptake of several recently launched infant formula products, including the first formulas in the U.S. with a human milk oligosaccharide that offers a unique immune-nourishing prebiotic. International sales declined 13.1 percent on a reported basis and 11.2 percent on an operational basis. Challenging market conditions in China and market softness in Saudi offset continued strong performance in Latin America and Southeast Asia.

Worldwide Adult Nutrition sales decreased 1.4 percent on a reported basis in the fourth quarter, including an unfavorable 1.0 percent effect of foreign exchange, and decreased 0.4 percent on an operational basis. In the quarter, worldwide growth of Ensure® was offset primarily by a difficult comparison to fourth quarter 2015, which included new product distributions in the U.S. and China.

Diagnostics
($ in millions)









% Change vs. 4Q15



Sales 4Q16




Int'l


Total



U.S.


Int'l


Total


U.S.


Reported


Operational


Reported


Operational

Total 


375


881


1,256


2.0


3.3


4.8


2.9


3.9

Core Laboratory


225


779


1,004


3.7


3.6


5.2


3.6


4.8

Molecular


44


73


117


(5.6)


(8.8)


(7.7)


(7.6)


(6.9)

Point of Care


106


29


135


2.0


37.6


37.2


8.1


8.0



























% Change vs. 12M15



Sales 12M16




Int'l


Total



U.S.


Int'l


Total


U.S.


Reported


Operational


Reported


Operational

Total 


1,437


3,376


4,813


3.2


3.8


6.5


3.6


5.5

Core Laboratory


841


3,003


3,844


3.5


3.8


6.6


3.7


5.9

Molecular


184


272


456


(3.9)


(1.2)


1.4


(2.3)


(0.8)

Point of Care


412


101


513


6.1


19.4


19.6


8.5


8.5

Worldwide Diagnostics sales increased 2.9 percent on a reported basis in the fourth quarter, including an unfavorable 1.0 percent effect of foreign exchange, and increased 3.9 percent on an operational basis.  

Core Laboratory Diagnostics sales increased 3.6 percent on a reported basis in the fourth quarter, including an unfavorable 1.2 percent effect of foreign exchange, and increased 4.8 percent on an operational basis. During the quarter, Abbott obtained CE Mark for several Alinity core laboratory systems, including "Alinity s" for blood and plasma screening, "Alinity c" for clinical chemistry, and "Alinity i" for immunoassay diagnostics. These instruments belong to Abbott's new Alinity family of harmonized systems, which were designed to be more efficient – running more tests in less space, generating test results faster and minimizing human errors – while continuing to provide quality results. 

Molecular Diagnostics sales decreased 7.6 percent on a reported basis in the fourth quarter, including an unfavorable 0.7 percent effect of foreign exchange, and decreased 6.9 percent on an operational basis. As expected, the planned scale down of the genetics business offset growth in the infectious disease testing business.

Point of Care Diagnostics sales increased 8.1 percent on a reported basis in the fourth quarter, including a favorable 0.1 percent effect of foreign exchange, and increased 8.0 percent on an operational basis. Sales growth in the quarter was led by continued adoption of Abbott's i-STAT handheld system in the U.S. and ongoing international market expansion. During the quarter, Abbott obtained CE Mark for its i-STAT Alinity handheld portable blood testing system. By delivering results in ten minutes or less using only two to three drops of blood, i-STAT Alinity provides healthcare professionals the information needed to make fast and accurate medical decisions without ever leaving their patient's side.

Established Pharmaceuticals
($ in millions)









% Change vs. 4Q15



Sales 4Q16




Int'l


Total



U.S.


Int'l


Total


U.S.


Reported


Operational


Reported


Operational

Total


--


979


979


n/a


10.6


12.6


10.6


12.6

Key Emerging Markets


--


777


777


n/a


10.6


13.0


10.6


13.0

Other


--


202


202


n/a


10.8


10.6


10.8


10.6











































% Change vs. 12M15



Sales 12M16




Int'l


Total



U.S.


Int'l


Total


U.S.


Reported


Operational


Reported


Operational

Total


--


3,859


3,859


n/a


3.7


10.5


3.7


10.5

Key Emerging Markets


--


2,912


2,912


n/a


4.7


13.3


4.7


13.3

Other


--


947


947


n/a


0.9


2.0


0.9


2.0

Established Pharmaceuticals sales increased 10.6 percent on a reported basis in the fourth quarter, including an unfavorable 2.0 percent effect of foreign exchange, and increased 12.6 percent on an operational basis.

Key Emerging Markets include Brazil, Russia, India and China (BRIC), along with several additional emerging markets that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these key geographies increased 10.6 percent on a reported basis and 13.0 percent on an operational basis in the fourth quarter. Operational sales growth was led by double-digit growth in BRIC, which comprises approximately 45 percent of Abbott's Established Pharmaceuticals sales, as well as strong growth in several countries throughout Latin America, including Colombia, Mexico, Peru and Argentina.

Medical Devices
($ in millions)









% Change vs. 4Q15



Sales 4Q16




Int'l


Total



U.S.


Int'l


Total


U.S.


Reported


Operational


Reported


Operational

Total


527


827


1,354


4.7


4.2


4.7


4.4


4.7

Vascular


307


414


721


6.9


0.1


0.6


2.9


3.2

Diabetes Care


87


223


310


(14.1)


14.1


16.3


4.5


6.0

Medical Optics


133


190


323


15.4


2.9


1.5


7.7


6.9


















Vascular Product Lines:

















Coronary Devicesa)


202


348


550


2.6


(1.4)


(1.0)


--


0.3

Endovascularb)


77


65


142


7.1


8.9


10.3


8.0


8.6


















a)Includes DES / BVS product portfolio, structural heart, guidewires, balloon catheters and other coronary products.

b)Includes vessel closure, carotid stents and other peripheral products.











% Change vs. 12M15



Sales 12M16




Int'l


Total



U.S.


Int'l


Total


U.S.


Reported


Operational


Reported


Operational

Total


2,047


3,186


5,233


3.2


4.1


5.4


3.8


4.5

Vascular


1,247


1,649


2,896


8.8


0.1


1.5


3.7


4.5

Diabetes Care


325


817


1,142


(17.4)


13.0


15.9


2.3


4.1

Medical Optics


475


720


1,195


7.2


4.4


3.7


5.5


5.1


















Vascular Product Lines:

















Coronary Devicesa)


799


1,387


2,186


4.0


(1.5)


(0.2)


0.5


1.3

Endovascularb)


303


259


562


7.4


9.0


11.3


8.1


9.2


















a)Includes DES / BVS product portfolio, structural heart, guidewires, balloon catheters and other coronary products.

b)Includes vessel closure, carotid stents and other peripheral products.

Worldwide Medical Devices sales increased 4.4 percent on a reported basis in the fourth quarter, including an unfavorable 0.3 percent effect of foreign exchange, and increased 4.7 percent on an operational basis.

Worldwide sales of Vascular products increased 2.9 percent on a reported basis in the fourth quarter, including an unfavorable 0.3 percent effect of foreign exchange, and increased 3.2 percent on an operational basis. Sales growth in Vascular products was led by double-digit growth of MitraClip®, Abbott's device for the treatment of mitral regurgitation, as Abbott continues to build the market for this first-in-class device. Strong sales growth in Abbott's Endovascular business was driven by vessel closure products and Supera®, Abbott's unique stent for the treatment of blockages in the leg.

Worldwide Diabetes Care sales increased 4.5 percent on a reported basis in the fourth quarter, including an unfavorable 1.5 percent effect of foreign exchange, and increased 6.0 percent on an operational basis. Double-digit international sales growth was driven by continued consumer uptake of FreeStyle® Libre, Abbott's revolutionary continuous glucose monitoring system that eliminates the need for finger-sticks.

Worldwide Medical Optics sales increased 7.7 percent on a reported basis in the fourth quarter, including a favorable 0.8 percent effect of foreign exchange, and increased 6.9 percent on an operational basis. Operational sales growth was driven by the recent U.S. launch of the TECNIS® Symfony intraocular lenses, the first and only lenses in the U.S. that provide a full range of continuous high-quality vision following cataract surgery.

ABBOTT ISSUES EARNINGS-PER-SHARE OUTLOOK FOR 2017

Abbott is issuing full-year 2017 guidance for diluted earnings per share from continuing operations under Generally Accepted Accounting Principles (GAAP) of $0.92 to $1.02, including amortization and integration expenses related to the acquisition of St. Jude Medical. 

Abbott forecasts net specified items for the full year 2017 of approximately $1.48 per share. Specified items include acquisition-related expenses, intangible amortization expense, charges associated with cost reduction initiatives and other expenses, partially offset by a gain on the sale of the Abbott Medical Optics business (AMO).

Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $2.40 to $2.50 for the full year 2017. 

Abbott is issuing first-quarter 2017 guidance for diluted earnings per share from continuing operations under GAAP of $0.19 to $0.21. Abbott forecasts specified items for the first quarter 2017 of $0.23 related to the same items discussed above for the full year 2017. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $0.42 to $0.44 for the first quarter.

ABBOTT ANNOUNCES INCREASE IN QUARTERLY DIVIDEND

On Dec. 9, 2016, the board of directors of Abbott increased the company's quarterly dividend to $0.265 per share from $0.260 per share. Abbott's cash dividend is payable Feb. 15, 2017, to shareholders of record at the close of business on Jan. 13, 2017. This marks the 372nd consecutive quarterly dividend paid by Abbott.

Abbott has increased its dividend payout for 45 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

About Abbott:

Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 94,000 people.

Visit Abbott at www.abbott.com and connect with us on Twitter at @AbbottNews.

Abbott will webcast its live fourth-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the call will be available later that day.

— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors''  to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2015, and St. Jude Medical's Annual Report on Form 10-K for the fiscal year ended Jan. 2, 2016, respectively, and under the heading "Risk Factors" in Abbott's Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, and St. Jude Medical's Quarterly Report on Form 10-Q for the fiscal quarter ended April 2, 2016, which are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

Fourth Quarter Ended December 31, 2016 and 2015

(in millions, except per share data)

(unaudited)




4Q16


4Q15


% Change


Net Sales


$5,333


$5,188


2.8










Cost of products sold, excluding amortization expense


2,312


2,206


4.8


Amortization of intangible assets


121


143


(15.0)


Research and development


343


369


(7.3)


Selling, general, and administrative


1,609


1,655


(2.8)


Total Operating Cost and Expenses


4,385


4,373


0.3










Operating earnings


948


815


16.3










Interest expense, net


129


9


n/m

1)

Net foreign exchange (gain) loss


(2)


(30)


(94.0)


Other (income) expense, net


(54)


6


n/m


Earnings from Continuing Operations before taxes


875


830


5.4










Taxes on Earnings from Continuing Operations


110


135


(17.9)


Earnings from Continuing Operations


765


695


9.9










Earnings from Discontinued Operations, net of taxes


33


72


(54.4)

2)









Net Earnings


$798


$767


3.9










Net Earnings from Continuing Operations, excluding 








Specified Items, as described below


$971


$932


4.2

3)









Diluted Earnings per Common Share from:








Continuing Operations


$0.51


$0.46


10.9


Discontinued Operations


0.02


0.05


(60.0)


Total


$0.53


$0.51


3.9










Diluted Earnings per Common Share from Continuing 








Operations, excluding Specified Items, as described below


$0.65


$0.62


4.8

3)









Average Number of Common Shares Outstanding








Plus Dilutive Common Stock Options 


1,483


1,498





NOTES:


See tables below for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes below.

1)

2016 Interest expense, net includes amortization expense associated with bridge facility fees and interest expense associated with $15.1 billion of debt issued in November 2016.



2)

2016 and 2015 Earnings and Diluted Earnings per Common Share from Discontinued Operations primarily reflect net favorable adjustments to tax expense as a result of the resolution of various tax positions from previous years related to discontinued operations.



3)

2016 Net Earnings from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $206 million, or $0.14 per share, for intangible amortization expense, expenses primarily associated with acquisitions, including bridge facility fees and other debt related costs, charges related to cost reduction initiatives and other expenses.




2015 Net Earnings from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $237 million, or $0.16 per share, for intangible amortization expense, expenses associated with cost reduction initiatives and other expenses related to acquisitions.

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

Fiscal Year Ended December 31, 2016 and 2015

(in millions, except per share data)

(unaudited)




12M16


12M15


% Change


Net Sales


$20,853


$20,405


2.2










Cost of products sold, excluding amortization expense


9,024


8,747


3.2


Amortization of intangible assets


550


601


(8.4)


Research and development


1,422


1,405


1.2


Selling, general, and administrative


6,672


6,785


(1.7)


Total Operating Cost and Expenses


17,668


17,538


0.7










Operating earnings


3,185


2,867


11.1










Interest expense, net


332


58


n/m

1)

Net foreign exchange (gain) loss


495


(93)


n/m

2)

Other (income) expense, net


945


(281)


n/m

3)

Earnings from Continuing Operations before taxes


1,413


3,183


(55.6)










Taxes on Earnings from Continuing Operations


350


577


(39.2)

4)

Earnings from Continuing Operations


1,063


2,606


(59.2)










Earnings from Discontinued Operations, net of taxes


321


65


n/m


Gain on Sale of Discontinued Operations, net of taxes


16


1,752


(99.1)


Net Earnings from Discontinued Operations, net of taxes


337


1,817


(81.4)

5)









Net Earnings


$1,400


$4,423


(68.4)










Net Earnings from Continuing Operations, excluding 








Specified Items, as described below


$3,281


$3,258


0.7

6)









Diluted Earnings per Common Share from:








Continuing Operations


$0.71


$1.72


(58.7)


Discontinued Operations


0.23


1.20


(80.8)

5)

Total


$0.94


$2.92


(67.8)










Diluted Earnings per Common Share from Continuing 








Operations, excluding Specified Items, as described below


$2.20


$2.15


2.3

6)









Average Number of Common Shares Outstanding








Plus Dilutive Common Stock Options 


1,483


1,506





NOTES:


See tables below for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes below.

1)

2016 Interest expense, net includes amortization expense primarily associated with bridge facility fees.



2)

2016 Net foreign exchange (gain) loss includes a loss of $480 million related to the revaluation of Abbott's net monetary assets in Venezuela using the Dicom exchange rate, which is the Venezuelan government's official floating exchange rate.



3)

2016 Other (income) expense, net includes a charge of $947 million related to an adjustment of Abbott's holdings of Mylan N.V. ordinary shares to reflect the share price as of Sept. 30, 2016.




2015 Other (income) expense, net includes a gain on the sale of a portion of Abbott's position in Mylan stock and a decrease in the fair value of contingent consideration related to a business acquisition, both reported as specified items.



4)

2016 Tax expense on Earnings from Continuing Operations includes the impact of a net tax benefit of approximately $225 million, primarily as a result of the resolution of various tax positions from prior years, partially offset by the unfavorable impact of non-deductible foreign exchange losses related to Venezuela and an adjustment to the equity investment in Mylan and the recognition of deferred taxes associated with the pending sale of AMO.



5)

2016 Earnings, net of taxes and Diluted Earnings per Common Share from Discontinued Operations primarily reflect the impact of a net tax benefit of $325 million as a result of the resolution of various tax positions from prior years.




2015 Earnings, net of taxes and Diluted Earnings per Common Share from Discontinued Operations reflect the after-tax gain of $1.752 billion on the sale of the developed markets branded generics pharmaceuticals and animal health businesses to Mylan on Feb. 27, 2015 and Zoetis on Feb. 10, 2015, respectively; the first-quarter financial results from these businesses up to the date of sale; and a favorable adjustment to tax expense as a result of the resolution of various tax positions from previous years related to discontinued operations.



6)

2016 Net Earnings from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $2.218 billion, or $1.49 per share, for intangible amortization expense, the foreign exchange loss related to Venezuela, an adjustment to the equity investment in Mylan, expenses associated with acquisitions, including bridge facility fees, other charges related to cost reduction initiatives and other expenses and the recognition of deferred taxes associated with the pending sale of AMO, partially offset by the favorable impact of a net tax benefit as a result of the resolution of various tax positions from prior years. 




2015 Net Earnings from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $652 million, or $0.43 per share, for intangible amortization expense, expenses associated with cost reduction initiatives and other expenses related to acquisitions, partially offset by a gain on the sale of a portion of Abbott's position in Mylan stock and a decrease in the fair value of contingent consideration related to a business acquisition.

NON-GAAP RECONCILIATION OF FINANCIAL INFORMATION FROM CONTINUING OPERATIONS

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information From Continuing Operations

Fourth Quarter Ended December 31, 2016 and 2015

(in millions, except per share data) 

(unaudited)




4Q16



As
Reported
(GAAP) 


Specified
Items


As
Adjusted


% to
Sales










Intangible Amortization


$121


$(121)


--



Gross Margin


2,900


161


$3,061


57.4%

R&D


343


(9)


334


6.3%

SG&A


1,609


(99)


1,510


28.3%

Interest expense, net


129


(101)


28



Net foreign exchange (gain) loss


(2)


1


(1)



Other (income) expense, net


(54)


52


(2)



Earnings from Continuing Operations before taxes 


875


317


1,192



Taxes on Earnings from Continuing Operations


110


111


221



Net Earnings from Continuing Operations


765


206


971



Diluted Earnings per Share from Continuing Operations


$0.51


$0.14


$0.65



Specified items reflect intangible amortization expense of $121 million and other expenses of $196 million, primarily associated with acquisitions, including bridge facility fees and other debt related costs, charges related to cost reduction initiatives and other expenses.



4Q15



As
Reported
(GAAP)


Specified
Items


As
Adjusted 


% to
Sales










Intangible Amortization


$143


$(143)


--



Gross Margin


2,839


178


$3,017


58.2%

R&D


369


(4)


365


7.0%

SG&A


1,655


(117)


1,538


29.6%

Other (income) expense, net


6


(6)


--



Earnings from Continuing Operations before taxes


830


305


1,135



Taxes on Earnings from Continuing Operations


135


68


203



Net Earnings from Continuing Operations


695


237


932



Diluted Earnings per Share from Continuing Operations


$0.46


$0.16


$0.62



Specified items reflect intangible amortization expense of $143 million and other expenses of $162 million, primarily associated with cost reduction initiatives and acquisitions.

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information From Continuing Operations

Fiscal Year Ended December 31, 2016 and 2015

(in millions, except per share data) 

(unaudited)




12M16



As
Reported
(GAAP) 


Specified
Items


As
Adjusted


% to
Sales










Intangible Amortization


$550


$(550)


--



Gross Margin


11,279


661


$11,940


57.3%

R&D


1,422


(77)


1,345


6.5%

SG&A


6,672


(249)


6,423


30.8%

Interest expense, net


332


(240)


92



Net foreign exchange (gain) loss


495


(480)


15



Other (income) expense, net


945


(910)


35



Earnings from Continuing Operations before taxes 


1,413


2,617


4,030



Taxes on Earnings from Continuing Operations


350


399


749



Net Earnings from Continuing Operations


1,063


2,218


3,281



Diluted Earnings per Share from Continuing Operations


$0.71


$1.49


$2.20



Specified items reflect intangible amortization expense of $550 million, an adjustment to the equity investment in Mylan of $947 million, the impact of the foreign exchange loss in Venezuela of $480 million, and other expenses of $640 million, primarily associated with acquisitions, including bridge facility fees, and charges related to cost reduction initiatives and other expenses and the recognition of approximately $70 million of deferred taxes associated with the pending sale of AMO, partially offset by a net tax benefit of approximately $225 million, primarily as a result of the resolution of various tax positions from prior years.



12M15



As
Reported
(GAAP) 


Specified
Items


As
Adjusted


% to
Sales










Intangible Amortization


$601


$(601)


--



Gross Margin


11,057


755


$11,812


57.9%

R&D


1,405


(85)


1,320


6.5%

SG&A


6,785


(272)


6,513


31.9%

Other (income) expense, net


(281)


288


7



Earnings from Continuing Operations before taxes 


3,183


824


4,007



Taxes on Earnings from Continuing Operations


577


172


749



Net Earnings from Continuing Operations


2,606


652


3,258



Diluted Earnings per Share from Continuing Operations


$1.72


$0.43


$2.15



Specified items reflect intangible amortization expense of $601 million and other expenses of $510 million, primarily associated with cost reduction initiatives and acquisitions, partially offset by a gain on the sale of a portion of Abbott's position in Mylan stock of $207 million and a decrease in the fair value of contingent consideration related to a business acquisition.

RECONCILIATION OF TAX RATE FOR CONTINUING OPERATIONS
A reconciliation of the fourth-quarter tax rates for continuing operations for 2016 and 2015 is shown below:




4Q16


($ in millions)


Pre-Tax
Income


Taxes on
Earnings


Tax
Rate


As reported (GAAP)


$875


$110


12.7%


Specified items


317


111




Excluding specified items


$1,192


$221


18.6%














4Q15


($ in millions)


Pre-Tax
Income


Taxes on
Earnings


Tax
Rate


As reported (GAAP)


$830


$135


16.3%


Specified items


305


68




Excluding specified items


$1,135


$203


17.9%

1)



1)

Fourth-quarter 2015 tax rate includes the year-to-date impact of U.S. tax legislation passed in Dec. 2015, including the R&D tax credit.

A reconciliation of the full-year tax rates for continuing operations for 2016 and 2015 is shown below:




12M16


($ in millions)


Pre-Tax
Income


Taxes on
Earnings


Tax
Rate


As reported (GAAP)


$1,413


$350


24.8%


Specified items


2,617


399




Excluding specified items


$4,030


$749


18.6%














12M15


($ in millions)


Pre-Tax
Income


Taxes on
Earnings


Tax
Rate


As reported (GAAP)


$3,183


$577


18.1%


Specified items


824


172




Excluding specified items


$4,007


$749


18.7%

2)



2)

Full-year 2015 tax rate includes the impact of U.S. tax legislation passed in Dec. 2015, including the R&D tax credit.

SOURCE Abbott

Related Links

http://www.abbott.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Also from this source

Abbott Hosts Conference Call for Third-Quarter Earnings

Abbott Hosts Conference Call for Third-Quarter Earnings

Abbott (NYSE: ABT) will announce its third-quarter 2025 financial results on Wednesday, Oct. 15, before the market opens. The announcement will be...

Abbott Declares 407th Consecutive Quarterly Dividend

Abbott Declares 407th Consecutive Quarterly Dividend

The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 59 cents per share. This marks the 407th consecutive...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

Household, Consumer & Cosmetics

Household, Consumer & Cosmetics

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.